Skip to main content
DHC logo

DHC · Diversified Healthcare Trust

Track DHC — free
$7.08 +0.05 (+0.71%)
Market Cap
$1.70B
Shares
242.53M
Volume · Nov 20 169.41K Avg daily vol (3M) 1.8M

Price & Indicators

 

Key stats

Close
$7.03
Open
$7.24
Day range
$7.00–7.25
52-week closing range
$4.45–9.64
Average volume, 30 days
1.7M
Short interest
12.0M · 4.9% of shares · 8.1 days
Short volume, last session
43%
Last earnings
Nov 3, 2026
Latest filing
10-Q · Nov 2
Price history
Jan 2020 to Nov 2026

Up next

Feb 23, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 16
Current report 8-K
2026 guidance lowered by incentive management fee

Diversified Healthcare Trust updated full year 2026 guidance to $0.46 - $0.52 of Normalized FFO per common share and $110,700-$125,700 of Normalized FFO, reflecting a $29,300 incentive management fee, while targeting 5.5x - 6.5x leverage.

Regulation FD disclosure Read from the first part of this long document
5 source passages
Diversified Healthcare Trust (Nasdaq: DHC) is a $6.3 billion healthcare REIT positioned at the center of one of real estate’s strongest demographic trends – the rapid growth of the 80+ population. $0.46 - $0.52 Normalized FFO per Common Share(2)(3) $110,700-$125,700 Normalized FFO(2)(3) Reflects the impact of the estimated full year 2026 incentive management fee of $29,300, or $0.12 per share, as of September 30, 2026. DHC is updating its targeted leverage outlook to 5.5x - 6.5x (excluding estimated incentive fees) to enhance its cost of capital and improve its outlook with the rating agencies. Open the document at this passage
Nov 3
Earnings call
Third-quarter NOI rises 27.5%, lifting shop outlook

DHC reported third-quarter consolidated NOI of $80.8 million, up 27.5%, and raised same-property shop NOI guidance by $5 million at the midpoint to $190 to $200 million while reducing recurring capital expenditure guidance by $10 million.

3 source passages
Following the market close yesterday, DHC reported normalized FFO of $30.7 million, or $0.13 per share, and adjusted EBITDA RE of $73.4 million, an increase of 28.4% year-over-year. Same property cash basis NOI increased 25.6% to $77.9 million, and consolidated NOI increased 27.5% to $80.8 million. Excluding the presentation change regarding estimated incentive fees, we are raising our SHOP SANE Property NOI Guidance by $5 million at the midpoint to $190 to $200 million, and that increase flows through to adjusted EBITDA RE and normalized FFO. We are reducing our 2026 recurring CapEx guidance by $10 million at the midpoint to $90 to $105 million. Open the document at this passage
Nov 2
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net loss narrows as SHOP occupancy and NOI improve

For the three months ended September 30, 2026, Diversified Healthcare Trust reported a net loss of 50,229 (dollars in thousands) versus 164,040, as NOI rose 27.5% to 80,763 and comparable SHOP occupancy increased to 84.4% from 82.4%.

Revenue $367.67M ▼ 5.4% Net loss $50.23M Diluted EPS -$0.21
Read from the MD&A section
4 source passages
Three Months Ended September 30, 2026 Compared to Three Months Ended September 30, 2025 (amounts in thousands, except per share data): | Occupancy | 84.4 | % | 82.4 | % | 83.8 | % | 81.5 | % | | NOI | 79,415 | 62,478 | 16,937 | 27.1% | 1,348 | 841 | 80,763 | 63,319 | 17,444 | 27.5% | | Net loss | (50,229) | (164,040) | 113,811 | (69.4)% | Open the document at this passage
Nov 2
Current report 8-K
Strong Q3 operating gains, reduced full-year guidance

Diversified Healthcare Trust reported same-property cash basis NOI growth of 25.6% to $77.9 million and Adjusted EBITDAre growth of 28.4% to $73.4 million for the quarter ended September 30, 2026. It lowered full year 2026 Normalized FFO guidance to $110,700 - $125,700.

Financial results Read from the first part of this long document
3 source passages
Diversified Healthcare Trust (Nasdaq: DHC) today announced its financial results for the quarter ended September 30, 2026. our third quarter results reflect the continued momentum DHC is experiencing from the strategic initiatives we have implemented over the past two years. This has translated into stronger operating and financial performance, as our same property cash basis NOI increased 25.6% year over year to $77.9 million and Adjusted EBITDAre increased 28.4% to $73.4 million. Normalized FFO (2) $135,000 - $150,000 $29,300 ($24,300) $110,700 - $125,700 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.48B
Trailing 12 months
Net income (TTM)
−$152.14M
Trailing 12 months
Revenue growth YoY
-5.4%
Year over year
Operating margin
—
Trailing 12 months
P / FFO
26.5×
Company-stated · FY2025 · reciprocal yield 3.8%
P / E (TTM)
—
Trailing earnings
Return on invested capital
—
Trailing 12 months
Net cash
−$2.33B
Latest balance sheet
Dividend yield
0.6%
Trailing 12 months
Shares change YoY
+0.2%
Year over year · more shares
Price change (1Y)
+55.9%
Trailing year
Short interest
4.9%
Latest settlement · 8.1 days to cover
View all 129 metrics

AI Brief

Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26

TL;DR. DHC reported strong Q2 results with 37.2% YoY same-property SHOP NOI growth and reaffirmed recently raised full-year guidance, while reducing 2026 SHOP occupancy and revenue growth assumptions (offset by improved expense control) and announcing new operator contracts set to begin January 2027.

Bullish
  • + Same-property SHOP NOI grew 37.2% YoY to $52 million with margins expanding 390 bps to 17.3%.
  • + Medical office leasing was robust with 477,000 sq ft at 6.7% rent roll-up and 7.1-year weighted average lease term.
  • + Full-year 2026 guidance was reaffirmed at raised levels, with SHOP NOI tracking toward high end.
Bearish
  • − SHOP top-line pacing below initial 2026 projections with occupancy gains slower than expected.
  • − Q2 shop same-store NOI included a ~$1.5 million one-time expense benefit not expected to repeat.
  • − Three known MOB/life science tenant vacates representing ~4.6% of segment annualized revenue, with two effective July 1.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −11%
below
Price vs 50-day avg −8%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 50%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −11%
trailing
6-month return −14%
trailing
YTD return +45%
this year
Relative strength −9%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow Distributing
-0% holders QoQ · +24 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.95% of shares out · ▲ +2.1% MoM · 8.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
242 holders — near 3-yr high, broad support
Squeeze score 63
elevated · 0–100
Fundamentals
Fair
Revenue growth +2%
Y/Y
EPS growth +23%
Y/Y
Balance sheet $2.3B
net debt
Quant / Vol
risk profile
High
Volatility 38%
annualized · 1-yr
Max drawdown −27%
past year
ATR 4.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 3, 2026
Full Year 2026 Guidance
Adjusted EBITDA RE Non-GAAP Lowered $276M – $291M
Aug 4, 2026 $300M – $315M changed to Nov 3, 2026 $276M – $291M
Normalized FFO Non-GAAP $111M – $126M
Normalized FFO Non-GAAP Lowered $0.46 – $0.52
Aug 4, 2026 $0.56 – $0.62 changed to Nov 3, 2026 $0.46 – $0.52
Recurring capital expenditures $90M – $105M
effective January 1, 2027
Annual cost savings $2M
fourth quarter
NOI $2M
Previous outlook earlier release · from the 8-K filed Nov 2, 2026

Still-open targets the latest release did not restate under the same label.

First year annual rent · first year $8M
Normalized FFO per Share (2) · full year 2026 $0.46 – $0.52
Revenue · full year 2026 6.3%
Average monthly rate · full year 2026 5.6%
ExPOR · full year 2026 1.7%
Operating expenses · full year 2026 2.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−11% Bearish
Price vs 50-day avg
−8% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
50% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow Distributing
-0% holders QoQ · +24 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.95% of shares out · ▲ +2.1% MoM · 8.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
242 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $7 · 50% Range high $10
vs 200-day avg -11% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDAre non-GAAP $82.08M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
EBITDAre 66.74M (the result of another reconciliation in this filing)
+2.26M General and administrative expense paid in common shares
+9.99M Incentive management fees
+3.09M Acquisition and certain other transaction related costs
+0K Gain on insurance recoveries
+0K Loss on modification or early extinguishment of debt
+0K Adjustments to reflect DHC's share of Adjusted EBITDAre attributable to a former equity method investment
= Adjusted EBITDAre 82.08M
All Other NOI non-GAAP 7.24M the three months ended June 30, 2026 filing —
Average Monthly Rate $5,715 the three months ended June 30, 2026 —
Average monthly rate (SHOP, all properties) $5,693 Three months ended June 30, 2026 filing —
CAD non-GAAP 18.52M three months ended 6/30/2026 —
CAD per common share non-GAAP $0.08 three months ended 6/30/2026 —
Cash Basis NOI non-GAAP $84.23M the three months ended 6/30/2026 —
GAAP → non-GAAP reconciliation
NOI 84.44M (the result of another reconciliation in this filing)
-211K Non-cash adjustments
= Cash Basis NOI 84.23M
Communities transitioned to new and existing third party managers 116 the three months ended June 30, 2026 filing —
Consolidated NOI $84.44M Three Months Ended June 30, 2026 —
EBITDAre non-GAAP 66.74M three months ended 6/30/2026 —
GAAP → non-GAAP reconciliation
EBITDA 63.5M (the result of another reconciliation in this filing)
+629K Loss (gain) on sale of real estate
+0K Impairment of assets
-1.85M Equity in net earnings of investees
+4.46M Share of EBITDAre from unconsolidated joint ventures
+0K Adjustments to reflect DHC's share of EBITDAre attributable to a former equity method investment
= EBITDAre 66.74M
FFO non-GAAP 25.82M three months ended 6/30/2026 —
GAAP → non-GAAP reconciliation
GAAP Net loss -37.42M
+62.54M Depreciation and amortization
+629K Loss (gain) on sale of real estate
+0K Impairment of assets
-1.85M Equity in net earnings of investees
+1.92M Share of FFO from unconsolidated joint ventures
+0K Adjustments to reflect DHC's share of FFO attributable to a former equity method investment
= FFO 25.82M
FFO per common share non-GAAP $0.11 three months ended 6/30/2026 —
Gross Book Value of Unencumbered Properties $4B As of June 30, 2026 —
Medical Office and Life Science Portfolio NOI non-GAAP 23.71M the three months ended June 30, 2026 filing —
Net debt / total gross assets 36.1% As of and For the Three Months Ended 6/30/2026 —
Normalized FFO non-GAAP $38.9M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
FFO 25.82M (non-GAAP)
+9.99M Incentive management fees
+3.09M Acquisition and certain other transaction related costs
+0K Gain on insurance recoveries
+0K Loss on modification or early extinguishment of debt
+0K Adjustments to reflect DHC's share of Normalized FFO attributable to a former equity method investment
= Normalized FFO 38.9M
Occupancy 83.1% the three months ended June 30, 2026 —
Occupancy (SHOP, all properties) 82.5% Three months ended June 30, 2026 filing —
Properties 67 as of 6/30/2026 (Medical Office and Life Science Portfolio) —
Same Property Cash Basis NOI Medical Office and Life Science Portfolio $24.05M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
Cash Basis NOI 23.67M (non-GAAP)
+385K Cash Basis NOI of properties not included in same property results
= Same property Cash Basis NOI - Medical Office and Life Science Portfolio 24.05M
Same Property Cash Basis NOI SHOP $51.98M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
Cash Basis NOI 53.5M (non-GAAP)
-1.52M Cash Basis NOI of properties not included in same property results
= Same property Cash Basis NOI - SHOP 51.98M
Same property NOI non-GAAP $51.98M the three months ended 6/30/2026 —
Same Property Occupancy Medical Office and Life Science Portfolio 95.8% Three Months Ended June 30, 2026 —
Same Property Occupancy SHOP 83.1% Three Months Ended June 30, 2026 —
Same property SHOP NOI margin 17.3% Q2 2026 —
SHOP NOI non-GAAP 53.5M the three months ended June 30, 2026 filing —
SHOP Same Property Average Monthly Rate Growth 6.2% Three Months Ended June 30, 2026 —
Square feet of new and renewal leasing (Medical Office and Life Science Portfolio) 477,000 Three Months Ended June 30, 2026 —
Total capital expenditures $25.8M the three months ended June 30, 2026 filing —
Total Liquidity $266.8M As of June 30, 2026 —
Units 22,469 As of and For the Three Months Ended 6/30/2026 —
Weighted average lease term (Medical Office and Life Science leasing) 7.1 Three Months Ended June 30, 2026 —
Weighted average lease term (years, total leases) 7.1 Three months ended June 30, 2026 filing —
Weighted average rent change on leasing (Medical Office and Life Science Portfolio) 6.7% Three Months Ended June 30, 2026 —
Weighted average rent coverage (triple net leased, all properties) 2.78 Three months ended June 30, 2026 filing —
Weighted average rental rate change (by rentable square feet, total leases) 6.7% Three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

REIT - Healthcare Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DHC
Diversified Healthcare Trust
this stock
$1.70B +44.9% +1.6% — 4.9%
WELL
Welltower Inc.
$178.41B +31.0% +35.6% 105.7 2.4%
VTR
Ventas, Inc.
$46.01B +12.4% +18.5% 164.2 2.8%
OHI
Omega Healthcare Investors Inc
$13.97B +3.6% +13.2% 18.4 4.8%
AHR
American Healthcare REIT, Inc.
$13.37B +22.4% +9.1% 115.2 14.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
242
% held
85.7%
Net QoQ
+2.1M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
220
View
Short & Settlement
Short Interest Rising
Shares short
12.0M
Days to cover
8.1d
Change
+247.4K sh
View
Short Volume
Short vol %
43%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
6.9K
Value
$54.7K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
39.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.5B
Net income (FY)
$-285.9M
EPS diluted
$-1.19
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
20

Diversified Healthcare Trust updated full year 2026 guidance to $0.46 - $0.52 of Normalized FFO per common share and $110,700-$125,700 of Normalized FFO, reflecting a $29,300 incentive management fee, while targeting 5.5x - 6.5x leverage.

View
Earnings & Events
Webcasts
Last webcast
Nov 3, 2026
View
Investor Relations
Latest news
Diversified Healthcare Trust Anno…
Published
Jul 9, 2026
View

Performance

5D 20D 120D MTD YTD
DHC -3.6% -10.7% -14.4% -9.6% +45.0%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +1.9% -4.4% -8.7% -4.4% +40.0%

Capital returns

Latest dividend
$0.01 / share · ex Oct 19, 2026
Cut 93.3%
Paid (TTM)
$0.04 / share · 4 payouts
Dividend yield (TTM, derived)
0.57%
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1075415 CUSIP 25525P107 13F (30d) 259 filings 220 filers Visit website Investor relations